What one share of Beta Bionics holds
We are a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease.
Beta Bionics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.69 |
|---|---|
| Profit | −$1.65 |
| Capex (buildings and equipment) | $0.13 |
| Free cash flow | −$1.39 |
| Cash and investments | $0.99 |
| Book value | $5.70 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $2.26 | −$8.31 | $0.08 | −$6.19 | — | −$38.30 |
| 2024 | $10.23 | −$8.60 | $0.53 | −$8.12 | — | −$36.80 |
| 2025 | $2.47 | −$1.81 | $0.13 | −$1.39 | — | $6.48 |
Common questions about Beta Bionics
How much does one share of Beta Bionics earn?
Over the last 12 months, Beta Bionics lost $1.65 for each share on $2.69 of sales.
Does Beta Bionics pay a dividend?
Beta Bionics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Beta Bionics’s book value per share?
Beta Bionics’s book value is $5.70 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Beta Bionics have?
Each share of Beta Bionics has $0.99 of cash and investments, as of June 30, 2026.
What is Beta Bionics’s free cash flow per share?
−$1.39 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.